Nanoparticle Formulation System

TAMARA is an R&D scale system that uses microfluidic technology to create RNA-LNP formulations.

The TAMARA RNA-LNP formulation system from Inside Therapeutics delivers high performance microfluidic synthesis of lipid nanoparticles (LNPs) with mRNA or siRNA payloads. It enables researchers to reliably produce uniform nanoparticles with >98% encapsulation efficiency in under 2 minutes, from low volume screening batches (200 µL) through to in vivo–scale runs (up to 30 mL).

TAMARA works by using advanced microfluidic chips to precisely mix the lipid–solvent and aqueous RNA phases under pressure-driven control.

Through controlled nanoprecipitation, TAMARA manages the four key stages of LNP formation—supersaturation, nucleation, growth, and stabilization—to deliver consistent particle quality. The system is engineered to minimise waste (no head or tail losses), so almost 100% of the active ingredient (API/RNA) is encapsulated, even at low volumes.

The TAMARA nanoparticle formulation system processes volumes from 0.2 mL (200 µL) up to 30 mL per batch. The system is designed for optimal efficiency, with guaranteed accuracy and repeatability across sample volumes from 0.5 to 5 mL.

TAMARA uses best in class pumps and advanced microfluidic chips to precisely accurately control the mixing conditions that impact encapsulation efficiency.  The system allows for fine-tuning of Total Flow Rate (TFR) and Flow Rate Ratio (FRR), resulting in a low polydispersity index (<0.2) and optimal nanoparticle size (~50–200 nm), directly correlating to high efficiency.

TAMARA completes individual sample formulation in under 2 minutes. For very low formulation volumes, the actual formulation runtime can be as short as ~3 seconds.

TAMARA is the only Microfluidic system that allows for precise low volume screening AND volumes sufficient for In-Vivo testing on the same device. It is the easiest to use because it doesn’t require syringes and most reproducible because it has recipe control capabilities.

TAMARA has also been proven to be able to create liposomes and polymer nanoparticles with very small size and low polydispersity.

TAMARA generates particles with low polydispersity index (<0.2) and optimal nanoparticle size (~50–200 nm), directly correlating to high efficiency.

TAMARA offers scale up to 30 mL which is sufficient for In-Vivo testing. Scale up from Microfluidic Chips to production volumes is generally avoided. Once the In-Vivo studies are completed, the process can be scaled up using conventional production processes like T-Mixers.

The TAMARA nanoparticle formulation system is the only system that is able to work with volumes as low as 200 uL and up to 30 mL. It is ideally suited to R&D research of its simplicity and reproducibility.

TAMARA also delivers best in class results; up to 98% encapsulation efficiency, excellent size control, highly uniform RNA-LNP particles, and up to 30% higher protein expression than conventional mixers.

It saves time and money by eliminating loss of valuable raw materials, using reusable low-cost chips. TAMARA combines two microfluidic designs on one chip so users can choose the best approach for their needs, providing an all-in-one system that replaces multiple machines from research through preclinical scale-up.